B66D 1/12 - Mécanismes d'entraînement comportant des moteurs électriques
B66D 1/46 - Dispositifs de commande non automatiques électriques
B66D 1/60 - Mécanismes d'enroulement des cordes, câbles ou chaînesCabestans adaptés à des usages particuliers
E01F 13/12 - Dispositions pour interdire ou limiter la circulation, p. ex. portes, barrières pour arrêter de force les véhicules ou les rendre inutilisables, p. ex. tapis cloutés
F41H 11/10 - Appareils pour leur mise en place, p. ex. dispositifs pour le déroulement ou l'enroulement du fil barbelé
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention relates to proteins suitable for treating or preventing an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.
The present invention relates to compounds of formula (I) as defined which are biologically active candidates for use in therapy. It also relates to pharmaceutical compositions comprising a compound of formula (I) or formula (II) as defined, methods and uses of compounds of formula (I) and formula (II), and compositions for preventing or treating inflammatory diseases or disorders, especially those associated with an interferon or interleukin, such as inflammatory bowel disease.
A61K 31/7034 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine
A61K 36/61 - Myrtaceae (famille du myrte), p. ex. cajeputier ou eucalyptus
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
C07H 15/207 - Cycles cyclohexane non substitués par des atomes d'azote, p. ex. kasugamycines
6.
A METHOD AND A SYSTEM FOR AUTOMATED PREDICTION OF CHARACTERISTICS OF AQUACULTURE ANIMALS
The present invention relates to a method and a system for automated prediction of characteristics (e.g. physical features and/or condition) of aquaculture animals.
G06F 18/2137 - Extraction de caractéristiques, p. ex. en transformant l'espace des caractéristiquesSynthétisationsMappages, p. ex. procédés de sous-espace basée sur des critères de préservation de la topologie, p. ex. positionnement multidimensionnel ou cartes auto-organisatrices
G06T 7/62 - Analyse des attributs géométriques de la superficie, du périmètre, du diamètre ou du volume
G06T 7/68 - Analyse des attributs géométriques de la symétrie
G06V 10/46 - Descripteurs pour la forme, descripteurs liés au contour ou aux points, p. ex. transformation de caractéristiques visuelles invariante à l’échelle [SIFT] ou sacs de mots [BoW]Caractéristiques régionales saillantes
G06V 40/10 - Corps d’êtres humains ou d’animaux, p. ex. occupants de véhicules automobiles ou piétonsParties du corps, p. ex. mains
C07K 14/44 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de protozoaires
A61K 39/018 - Antigènes de Babesia, p. ex. antigènes de Theileria
A61P 33/02 - Antiprotozoaires, p. ex. pour le traitement de la leishmaniose, de la trichomonase, de la toxoplasmose
The present invention relates to proteins suitable for treating or preventing an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
A61P 1/06 - Antispasmodiques, p. ex. médicaments pour le traitement des coliques, des dyskinésies œsophagiennes
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
The present invention provides recombinant strains of M. bovis BCG comprising a heterologous nucleic acid encoding a fusion protein, wherein the fusion protein comprises or consists of: a) a polypeptide that is at least about 80% identical to an ESAT-6 protein and b) a secretion peptide for enabling secretion of the polypeptide via an ESX-5 secretion system of M. bovis BCG.
A61K 39/04 - Mycobacterium, p. ex. Mycobacterium tuberculosis
A61P 31/06 - Agents antibactériens pour le traitement de la tuberculose
C07K 14/35 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de bactéries provenant de Mycobacteriaceae (F)
The present invention relates to a peptide for treating an inflammatory or autoimmune condition, pharmaceutical compositions comprising same, and methods of use comprising same.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 35/62 - SangsuesVers, p. ex. cestodes, nématodes, vers de terre, ascarides, filaires, ankylostomes, trichines ou ténias
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
11.
Growth performance improvements in pasture and feedlot systems
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 20/20 - Substances inorganiques, p. ex. oligo-éléments
A23K 20/24 - Composés de métaux alcalino-terreux, p. ex. de magnesium
A23K 40/10 - Mise en forme ou traitement des produits alimentaires pour animaux par agglomérationMise en forme ou traitement des produits alimentaires pour animaux par granulation, p. ex. fabrication de poudres
A23K 40/20 - Mise en forme ou traitement des produits alimentaires pour animaux par moulage, p. ex. fabrication de gâteaux ou de briquettes
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p. ex. Porphyra
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
13.
Modified anti-inflammatory proteins and method of use
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C-S-C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
AsparagopsisAsparagopsisAsparagopsis into an oil to form the compositions. These compositions are suitable for reducing total gas production and/or methane production in a ruminant or pseudo-ruminant animal.
42 - Services scientifiques, technologiques et industriels, recherche et conception
45 - Services juridiques; services de sécurité; services personnels pour individus
Produits et services
Business management; business administration; office
functions; business negotiation of contracts for others;
advisory services on acquisitions; advisory services on
commercial management; advisory services on business risk
management; business advice on contracts; business advice on
commercial agreements; business brokerage between
researchers and third parties; business consultancy;
commercial advice; commercial evaluation services;
commercial research and evaluation of commercial projects;
business negotiations of contracts for others; collaborative
business services for researchers, universities, potential
partners and others; business consultation for
commercialisation services; business consultation for
commercialisation of new technologies; business consultation
for commercialisation of intellectual property; company
management (for others); compilation of business data,
information and reports; consultancy on establishment of
businesses (for others); corporate analysis; cost analysis
and project pricing; data management; evaluation of business
opportunities; business grant preparation or advice;
intermediary services for the commercialisation of goods or
services; business management of ethics advice with respect
to approvals; management of business affairs for others
including arrangements with respect to research and
commercialisation; market investigations and research;
market analysis; preparation of commercial reports and
documentation; business project management; business
strategic planning; and advisory, consultancy,
documentation, information and reporting services for any of
the foregoing, including provided through wireless networks
or the cloud. Scientific research services; technological services;
scientific and technological research; scientific and
technological design; research services; scientific or
technical services in advising researchers, professional
advisors, or potential commercial partners and coordinating
and collaborating therebetween; industrial analysis;
scientific or technological brokerage services between
researchers and third parties; collaborative scientific or
research services for researchers, universities, potential
partners and others; commercial design services; conducting
trials and research; data storage; design consultancy;
design of prototypes; design and development of new
products; design of test equipment, products or methods;
ethics evaluation advice with respect to scientific research
approvals; evaluation of performance of tested new products;
industrial analysis; industrial research for new
technologies; intellectual property research; intellectual
property considerations, management or analysis (not legal);
intellectual property advisory services (not legal);
provision of scientific research and sharing of information
between parties; organisation for business purposes of
scientific research installations; preparation of reports in
this class; preparation of technical documentation in this
class; product or technology testing; product or technology
evaluation; project management (design); research and
development; research and development projects for others;
research and development of new technology projects, for
researchers and potential commercial partners; scientific
laboratory services; scientific or technological advice on
grant applications or management; technical studies;
technical advice on commercialisation of research, new
technologies or project materials; trade mark design; and
advisory, consultancy, documentation, information and
reporting services for any of the foregoing, including
provided through wireless networks or the cloud. Legal services and advice; advisory services with respect to
intellectual property rights; advisory services with respect
to patents for invention, trade secrets, commercially
sensitive information, trade marks or industrial designs;
advisory services with respect to common law intellectual
property rights; copyright management; legal ethics
evaluation advice with respect to approvals; legal
administrative services; legal advice relating to contract;
legal assistance in contract negotiation, preparation and
execution for others; legal assistance in the drawing up of
contracts between research parties and external parties,
including term negotiation; legal services in the drawing up
of contracts relating to intellectual property; legal
services in the drawing up of contracts relating to
commercialisation of technology; legal services in the
drawing up of contracts between multiple stakeholders in a
commercial or research project; due diligence searches
namely intellectual property searching services;
exploitation of intellectual property right services
including legal agreements and contract services; industrial
property advisory services; intellectual property advisory
services; intellectual property licensing services; legal
administration of licenses; legal brokerage services between
researchers and third parties for legal arrangements; legal
services and advice to researches; legal advice on grant
application and management; legal advice to potential
commercial or professional partners; legal advice between
researchers and potential commercialisation partners to
facilitate research or commercial projects; legal research;
legal research with respect to research, commercialisation
or intellectual property matters; licensing; licensing
arrangements with respect to research; management of
patents; management of trade marks; monitoring of
intellectual property matters; provision of legal research;
searches with respect to technology, intellectual property
or freedom to operate; searches of intellectual property
database; and advisory, consultancy, documentation,
information and reporting services for any of the foregoing,
including provided through wireless networks or the cloud.
16.
Growth performance improvements in pasture and feedlot systems
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
MEAT & LIVESTOCK AUSTRALIA LIMITED (Australie)
Inventeur(s)
Tomkins, Nigel William
De Nys, Rocky
Kinley, Robert Douglas
Magnusson, Marie Elisabeth
Machado, Lorenna
Paul, Nicholas Andrew
Abrégé
The invention relates to utilising red marine macroalgae to provide improvements in growth performance of livestock, particularly ruminant animals for red meat production, especially cattle, in pasture and feedlot farming systems. There is provided a method for improving the growth performance of a livestock animal in a farming system including: providing a red marine macroalgae to a farming system to enable consumption of the red marine macroalgae by a livestock animal in the farming system; thereby improving the growth performance of the livestock animal in the system.
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 40/20 - Mise en forme ou traitement des produits alimentaires pour animaux par moulage, p. ex. fabrication de gâteaux ou de briquettes
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 10/16 - Ajout de micro-organismes ou de leurs produits d’extraction, p. ex. de protéines provenant d’organismes unicellulaires, à des compositions de produits alimentaires
A23K 40/10 - Mise en forme ou traitement des produits alimentaires pour animaux par agglomérationMise en forme ou traitement des produits alimentaires pour animaux par granulation, p. ex. fabrication de poudres
A23K 20/20 - Substances inorganiques, p. ex. oligo-éléments
A23K 20/24 - Composés de métaux alcalino-terreux, p. ex. de magnesium
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p. ex. Porphyra
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
Peptides derived from the N-terminal region of granulin have activity in promoting cell proliferation, migration and/or wound healing. Furthermore, an additional disulphide bond may be engineered into such peptides to improve or otherwise modify the folding of the peptide. The peptides may also be modified such as at proline residues improve the ability of the peptide to promote cell proliferation.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
MEAT & LIVESTOCK AUSTRALIA LIMITED (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Tomkins, Nigel William
De Nys, Rocky
Kinley, Robert Douglas
Paul, Nicholas Andrew
Magnusson, Marie Elisabeth
Machado, Lorenna
Abrégé
The invention relates to utilising red marine macroalgae to provide improvements in growth performance of livestock, particularly ruminant animals for red meat production, especially cattle, in pasture and feedlot farming systems. There is provided a method for improving the growth performance of a livestock animal in a farming system including: providing a red marine macroalgae to a farming system to enable consumption of the red marine macroalgae by a livestock animal in the farming system; thereby improving the growth performance of the livestock animal in the system.
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A61K 36/04 - Rhodophycota ou rhodophyta (algues rouges), p. ex. Porphyra
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
An immunogenic composition comprises one or a plurality of isolated proteins comprising respective amino acid sequences set forth in SEQ ID NOS:1-3, or a fragment or variant thereof; one or a plurality of isolated nucleic acids encoding SEQ ID NOS:1-3, or a fragment or variant thereof; or an antibody which binds one or a plurality of isolated proteins comprising respective amino acid sequences set forth in SEQ ID NOS:1-3, or a fragment or variant thereof. The isolated protein may be a chimeric protein comprising two or more of SEQ ID NOS:1-3. The immunogenic composition preferably elicits a protective immune response to schistosomes in a mammal. Accordingly, methods of eliciting an immune response, immunization, prevention and/or treatment of schistosome infections are provided.
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C—S—C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
23.
METHOD FOR THE CULTIVATION AND PRODUCTION OF MACROALGAE
A method is provided for the cultivation and/or production of green macroalgae, such as Ulva spp. The green macroalgae are exposed to a temperature shock, such as a cold shock or a heat shock to induce reproduction, then maintained under suitable conditions. The method may further comprise fragmenting the temperature shocked green macroalgae. Green macroalgae may be produced according to the invention, such as for the production of biomass, wastewater treatment, bioremediation, human consumption, animal feed, and/or feedstock for the supply of pharmaceuticals, nutraceuticals, cosmeceuticals and/or biofuels. The method may be performed within a marine or brackish water environment, such as an aquaculture farm.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
MEAT & LIVESTOCK AUSTRALIA LIMITED (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Machado, Lorenna
Magnusson, Marie, Elisabeth
Tomkins, Nigel, William
Kinley, Robert, Douglas
De Nys, Peter, Canisius
Paul, Nicholas, Andrew
Abrégé
The present application relates to animal feed and feed supplements comprising red marine macroalgae species. The present application also relates to methods of reducing total gas production and/or methane production in a ruminant animal by administering red marine macroalgae species, or by administering feed or feed supplements comprising red marine macroalgae.
A method and composition for reducing or alleviating inflammation in a subject is provided, including administering to the subject a therapeutically effective amount; of one or more isolated proteins respectively comprising an amino acid sequence set forth in SEQ ID NOS:l-31, or a biologically active fragment or variant thereof or combinations of these to thereby reduce or alleviate inflammation. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
26.
MODIFIED ANTI-INFLAMMATORY PROTEINS AND METHOD OF USE
A modified Ac-TMP-2 protein lacks one or a plurality of acidic C-terminal amino acids normally present in a full-length or wild-type Ac-TMP-2 protein and may also lack one or a plurality of N-terminal amino acids while retaining the amino acid sequence C-S-C at or near the N-terminus. The modified Ac-TMP-2 protein may be useful in method and composition for reducing or alleviating inflammation in a subject. Inflammation may be associated with a disease is a disease of the digestive tract such as chronic gastritis or an inflammatory bowel disease such as Crohn's disease or ulcerative colitis, or a disease of the respiratory system, such as asthma, emphysema, chronic bronchitis, and chronic obstructive pulmonary disease.
C12N 15/15 - Inhibiteurs de protéases, p. ex. antithrombine, antitrypsine, hirudine
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
A61P 37/00 - Médicaments pour le traitement des troubles immunologiques ou allergiques
27.
COATING FOR AN IMPLANTABLE BIOMATERIAL, IMPLANTABLE BIOMATERIAL AND METHOD OF MAKING THE COATING AND BIOMATERIAL
The invention provides a coating for a biomaterial, the coating comprising monomeric units comprising a terpene or terpene analogue or derivative polymerised by plasma polymerisation. The invention also provides a method of coating a biomaterial in which monomeric units comprising a terpene or terpene analogue or derivative are polymerised with plasma polymerisation to form a polymer and the polymer is deposited as a coating on a biomaterial substrate. Also provided is a biomaterial comprising a substrate and the polymeric coating along with a method of making a biomaterial comprising polymerising terpene or terpene analogue or derivative monomeric units and depositing the polymer as a coating on a. biomaterial substrate. The invention also provides a method of reducing the degradation rate of a biomaterial.
A61L 27/58 - Matériaux au moins partiellement résorbables par le corps
B05D 3/14 - Traitement préalable des surfaces sur lesquelles des liquides ou d'autres matériaux fluides doivent être appliquésTraitement ultérieur des revêtements appliqués, p. ex. traitement intermédiaire d'un revêtement déjà appliqué, pour préparer les applications ultérieures de liquides ou d'autres matériaux fluides par des moyens électriques
C23C 4/04 - Revêtement par pulvérisation du matériau de revêtement à l'état fondu, p. ex. par pulvérisation à l'aide d'une flamme, d'un plasma ou d'une décharge électrique caractérisé par le matériau de revêtement
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
A biosorbent is provided which comprises algal based biomass coated with one or more metal cations, whereby the coated algal based biomass is capable of reducing or removing one or more oxyanions from water and/or another aqueous solution. Also provided is a method of using the biosorbent to at least partly remove one or more oxyanions from water and/or another aqueous solution, such as wastewater. In addition or alternatively, there is provided a method of removing metal cations from water and/or another aqueous solution, such as wastewater.
B01D 15/36 - Adsorption sélective, p. ex. chromatographie caractérisée par le mécanisme de séparation impliquant une interaction ionique, p. ex. échange d'ions, paire d'ions, suppression d'ions ou exclusion d'ions
A62D 3/02 - Procédés pour rendre les substances chimiques nuisibles inoffensives ou moins nuisibles en effectuant un changement chimique dans les substances par des procédés biologiques, c.-à-d. des procédés utilisant des enzymes ou des micro-organismes
C02F 1/42 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par échange d'ions
C02F 3/32 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout caractérisé par les animaux ou végétaux utilisés, p. ex. les algues
An improved bioreactor, method and system for cultivating microorganisms, in particular photosynthetic microorganisms. The bioreactor comprises at least one or a plurality of liquid permeable layers comprising a first surface and a second surface, wherein microorganisms are cultivatable on the first surface of the liquid permeable layer and the second surface is connectable in fluid communication with a fluid source, and wherein the liquid permeable layer is rotatable.
C12M 1/14 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens fournissant des couches minces ou avec des plateaux à niveaux multiples
C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
C02F 3/00 - Traitement biologique de l'eau, des eaux résiduaires ou des eaux d'égout
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of : (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Poole, Andrew James
De Nys, Rocky
King, Peter
Gulizia, Stefan
Jahedi, Mahnaz
Abrégé
A method of protecting a polymer surface against fouling, which method comprises embedding in the polymer surface particles having antifouling properties, wherein the particles are embedded in the polymer surface by a spray mechanism in which the particles are accelerated and sprayed onto the polymer surface with a suitable velocity such that the particles become embedded in the polymer surface, wherein the particles are embedded in the polymer surface without an adhesive or binder and wherein the particles do not form a continuous layer on the polymer surface.
B32B 27/04 - Produits stratifiés composés essentiellement de résine synthétique comme substance d'imprégnation, de collage, ou d'enrobage
B32B 15/08 - Produits stratifiés composés essentiellement de métal comprenant un métal comme seul composant ou comme composant principal d'une couche adjacente à une autre couche d'une substance spécifique de résine synthétique
B05D 1/12 - Application de matériaux en particules
B32B 15/20 - Produits stratifiés composés essentiellement de métal comportant de l'aluminium ou du cuivre
The present invention relates to ruthenium complexes, and in particular di- and multi- nuclear ruthenium complexes which may be used as antimicrobial agents. The invention also relates to pharmaceutical compositions comprising such complexes, and methods for their use in treating or preventing microbial infections.
The present invention discloses methods for assessing protease activity and fusion protein substrates suitable for use in such methods. The fusion protein substrates comprise a stable fluorescent protein, a linker and an unstable non- fluorescent protein, wherein the linker comprises a protease recognition sequence recognised by the protease to be quantified. More particularly, this invention relates to improved assays for quantifying protease activity.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
35.
A METHOD AND SYSTEM FOR LINEARISING A RADIO FREQUENCY TRANSMITTER
A method for linearising a multi-carrier radio frequency transmitter or a multi-user CDMA radio frequency transmitter enables improved linearisation. The method includes measuring a function of out-of-band signal power in the frequency domain at an output of the radio frequency transmitter. A digital base-band pre-distortion, performed by a digital base-band pre-distortion network, is then applied to the radio frequency transmitter according to the measured function of the out-of-band signal power.
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Poole, Andrew James
De Nys, Rocky
King, Peter
Gulizia, Stefan
Jahedi, Mahnaz
Abrégé
A method of protecting a polymer surface against fouling, which method comprises embedding in the polymer surface particles having antifouling properties, wherein, the particles are embedded in the polymer surface by a spray mechanism in which the particles are accelerated and sprayed onto the polymer surface with a suitable velocity such that the particles become embedded in the polymer surface, wherein the particles are embedded in the polymer surface without an adhesive or binder and wherein the particles do not form a continuous layer on the polymer surface.
The present invention relates generally to altering levels of components in the kallikrein-kinin system (KKS) to assist in preventing or treating aneurysms in an individual, and also to detecting the presence, determining the prognosis or monitoring the progression of an aneurysm by detecting aberrant expression of one or more genes in the kallikrein-kinin system (KKS). The invention also relates to methods for identifying agents that antagonise the KKS, and methods of producing agents comprising KKS antagonists for preventing or treating aneurysms.
The invention relates to methods and compositions for assessing protein stability, including improved assays for distinguishing between soluble and aggregated proteins. The methods and compositions include measuring residual fluorescence of a fusion protein in a soluble fraction as an indicator of protein solubility. The fusion protein may comprise an amino acid sequence of a protein of interest, a peptide linker amino acid sequence and an amino acid sequence of a fluorescent marker protein.
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
C12N 15/12 - Gènes codant pour des protéines animales
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C12N 15/62 - Séquences d'ADN codant pour des protéines de fusion
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
The present invention is a cooling garment, comprising at least one tubing matrix for location of a coolant; wherein the tubing matrix is in the form of a waffle design.
A41D 13/005 - Vêtements protecteurs de travail ou de sport, p. ex. blouses de chirurgien ou vêtements protégeant des coups ou des chocs avec des conditions d'environnement interne qui sont commandées avec une température commandée
A61F 7/00 - Appareils de chauffage ou de refroidissement pour traitement médical ou thérapeutique du corps humain
A62B 17/00 - Vêtements de protection contre la chaleur, les agents chimiques nuisibles ou pour l'emploi à haute altitude
The present invention relates to a method of detecting and/or quantifying a target molecule from a sample obtained from a subject wherein the method comprises: (i) incubating a fusion protein or conjugate comprising a Ter binding polypeptide fused to at least one anti-target molecule or fragment thereof with a partially double-stranded oligonucleotide for a time and under conditions sufficient to bind to said Ter binding polypeptide thereby producing a complex; (ii) incubating said complex in the presence of said sample comprising said target molecule for a time and under conditions sufficient for said anti-target molecule to bind to said target molecule thereby producing a target-bound complex; (iii) incubating said target-bound complex in the presence of at least one immobilised molecule wherein said immobilised molecule has an affinity to said target molecule; (iv) incubating said immobilised molecule for a time and under conditions sufficient to bind to said target molecule thus immobilising said target molecule; and (v) detecting and/or quantifying said target molecule.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
41.
METHOD FOR REDUCING INFLAMMATORY RESPONSES AND INFLAMMATION
ADELAIDE RESEARCH & INNOVATION PTY LTD (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Nimmo, Alan, John
Whitfield, Karen, Margaret
Reardon, Konrad
Vink, Robert
Abrégé
The present invention relates a method of preventing and/or reducing an inflammatory response and/or inflammation in one or more tissues. The method includes delivering to the one or more tissues an effective amount of a substance P receptor antagonist.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 31/405 - Acides indole-alkanecarboxyliquesLeurs dérivés, p. ex. tryptophane, indométhacine
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
42.
METHOD AND COMPOSITION FOR REDUCING REPERFUSION INJURY
ADELAIDE RESEARCH & INNOVATION PTY LTD (Australie)
JAMES COOK UNIVERSITY (Australie)
Inventeur(s)
Nimmo, Alan, John
Whitfield, Karen, Margaret
Turner, Renée, Jade
Vink, Robert
Abrégé
The present invention relates to a method of preventing and/or reducing reperfusion injury to a tissue, organ, or organ system in a subject. The method includes administering to the subject an effective amount of a substance P receptor antagonist.
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
43.
GROWTH PERFORMANCE IMPROVEMENTS IN PASTURE AND FEEDLOT SYSTEMS
COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION (Australie)
JAMES COOK UNIVERSITY (Australie)
MEAT AND LIVESTOCK AUSTRALIA LIMITED (Australie)
Inventeur(s)
Tomkins, Nigel William
De Nys, Rocky
Kinley, Robert Douglas
Paul, Nicholas Andrew
Magnusson, Marie Elisabeth
Machado, Lorenna
Abrégé
The invention relates to utilising red marine macroalgae to provide improvements in growth performance of livestock, particularly ruminant animals for red meat production, especially cattle, in pasture and feedlot farming systems. There is provided a method for improving the growth performance of a livestock animal in a farming system including: providing a red marine macroalgae to a farming system to enable consumption of the red marine macroalgae by a livestock animal in the farming system; thereby improving the growth performance of the livestock animal in the system.
A23K 10/30 - Produits alimentaires pour animaux à base de matières d’origine végétale, p. ex. de racines, de graines ou de foinProduits alimentaires pour animaux à base de matières d’origine fongique, p. ex. de champignons
A23K 50/10 - Produits alimentaires spécialement conçus pour des animaux spécifiques pour les ruminants
A method for reducing or alleviating inflammation in a subject includes administering to the subject a therapeutically effective amount of : (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby reduce or alleviate inflammation in the subject. A method for preventing or treating asthma or inflammatory bowel disease in a subject includes administering to the subject a therapeutically effective amount of: (a) Ac-TMP-1 or a biologically active fragment or variant of Ac-TMP-1; (b) Ac-TMP-2 or a biologically active fragment or variant of Ac-TMP-2; or (c) a combination of (a) and (b), to thereby prevent or treat asthma or inflammatory bowel disease in the subject. The subject may be a mammal, inclusive of humans.
A61K 38/57 - Inhibiteurs de protéases provenant d'animauxInhibiteurs de protéases provenant d'humains
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
45.
METHOD FOR REDUCING TOTAL GAS PRODUCTION AND/OR METHANE PRODUCTION IN A RUMINANT ANIMAL
